AI + Cancer – Advisory Board MemberAbout the Opportunity A cutting-edge spin-off from a world-renowned European academic institution is working where Artificial Intelligence, DNA and Oncology meet. Its science has been published in The Lancet Respiratory Medicine. The company is completing its Advisory Board and is now opening the AI Seat. The company is led by a US CEO with decades of experience in senior leadership positions across big pharma and CROs. The CEO has a track record of commercializing innovative assets across several therapeutic areas. The company is also supported, in different capacities, by President- and CEO-level leaders from big pharma and advanced analytics, alongside a Clinical Advisory Board of leading oncologists. This is an Advisory Board position involving periodic strategic engagement rather than full-time employment. The VisionCancer medicine is being reshaped by three converging trends: Precision medicine: moving from treating the average patient to choosing the right treatment for each individual. Reading cancer through DNA: DNA, and the chemical marks on it, carry a living record of how a cancer behaves and how the body responds to it. Artificial intelligence: models that find patterns in DNA sequences and in the interactions between a medicine, the tumor, the surrounding tissue and the immune system, to help win the fight against cancer. The company sits where these three trends meet. Its ambition is a platform that reads a patient's DNA from a blood sample and uses AI to guide decisions across the course of cancer care: before, during and after treatment. First Applications Predicting, before the first dose, whether cancer immunotherapy is likely to work Identifying patients at risk of metastasis Detecting early signs of relapse Advisory Board SeatAI SeatThe AI Seat brings an independent perspective on the questions that will define AI in cancer medicine over the next decade: Foundation models for biology: how DNA and epigenetic foundation models will change the way cancer is read from a blood sample. Multimodal AI: bringing together blood-based DNA signals, imaging, pathology and clinical history into a single, clinically meaningful prediction. AI that travels: making models perform reliably across hospitals, countries, patient populations and sequencing technologies. Learning diagnostics: how AI that improves over time fits emerging regulation, from the FDA's evolving framework for adaptive AI to the EU AI Act. Privacy-preserving AI: learning across hospitals worldwide without moving patient data. AI in drug development: using response prediction to select patients and design smarter clinical trials with pharmaceutical partners. Lasting advantage: where enduring value sits in AI-driven medicine, whether in data, models or clinical evidence.
Minimum Qualifications:
Candidates must have held a Chief AI Officer, Vice President, Senior Vice President, President or equivalent leadership position, with responsibility for AI strategy. This should be within a leading technology, pharmaceutical, biotechnology or diagnostics organization, or a leading AI research institution. Preferred Areas of ExpertiseAI Strategy Foundation Models and Generative AIAI in Healthcare and Life Sciences Oncology and Immuno-Oncology Genomics and Precision MedicineAI Regulation and Responsible AIStrategic Partnering Ideal Profile An AI leader with a worldwide reputation, who brings:a track record of taking AI from research to real-world impact at scale; a recognized voice in how AI is shaping medicine and the life sciences; a network spanning frontier AI, academia and the pharmaceutical industry. The Advisory Board will appoint the selected candidate based on leadership experience, track record and strategic expertise. Ideal candidates come from leading AI labs, global technology companies or AI-driven life sciences organizations.
